Song Paul Y. Insider Trades

Insider Trading History

Track insider trading activity for Song Paul Y.. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
NKGen Biotech- Warrants (01/09/2028)
NKGen Biotech- Warrants (01/09/2028) NKGNW
Chief Executive Officer
Holding Value $1.26M 41,699,449 shares
Last Trade
May 05, 2025 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$1.25M 62,549,174 shares
$0.02
$0.03
NKGen Biotech
NKGen Biotech NKGN
Chief Executive Officer
Holding Value $2.5M 41,699,449 shares
Last Trade
May 05, 2025 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$8.13M 62,549,174 shares
$0.13
$0.06
NKGen Biotech
NKGen Biotech NKGN
Chief Executive Officer
Holding Value $120k 2,000,000 shares
Last Trade
Dec 06, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$880k 2,000,000 shares
$0.44
$0.06
NKGen Biotech- Warrants (01/09/2028)
NKGen Biotech- Warrants (01/09/2028) NKGNW
Chief Executive Officer
Holding Value $60.2k 2,000,000 shares
Last Trade
Dec 06, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$89.2k 2,000,000 shares
$0.04
$0.03
NKGen Biotech
NKGen Biotech NKGN
Chief Executive Officer
Holding Value $75.6k 1,260,000 shares
Last Trade
Feb 12, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$2.04M 1,260,000 shares
$1.62
$0.06
NKGen Biotech- Warrants (01/09/2028)
NKGen Biotech- Warrants (01/09/2028) NKGNW
Chief Executive Officer
Holding Value $37.9k 1,260,000 shares
Last Trade
Feb 12, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$32.8k 1,260,000 shares
$0.03
$0.03
NKGen Biotech- Warrants (01/09/2028)
NKGen Biotech- Warrants (01/09/2028) NKGNW
Chief Executive Officer
Holding Value $5.15k 171,120 shares
Last Trade
Dec 07, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$12.2 76 shares
$0.16
$0.03
Graf Acquisition IV
Graf Acquisition IV GFOR
Chief Executive Officer
Holding Value $1.42M 171,120 shares
Last Trade
Dec 07, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$250 76 shares
$3.29
$8.30
NKGen Biotech
NKGen Biotech NKGN
Chief Executive Officer
Holding Value $10.3k 171,120 shares
Last Trade
Dec 07, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$250 76 shares
$3.29
$0.06
NKGen Biotech
NKGen Biotech NKGN
Chief Executive Officer
Holding Value $10.3k 171,044 shares
Last Trade
Dec 06, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$249 75 shares
$3.32
$0.06
Graf Acquisition IV
Graf Acquisition IV GFOR
Chief Executive Officer
Holding Value $1.42M 171,044 shares
Last Trade
Dec 06, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$249 75 shares
$3.32
$8.30
NKGen Biotech- Warrants (01/09/2028)
NKGen Biotech- Warrants (01/09/2028) NKGNW
Chief Executive Officer
Holding Value $5.15k 171,044 shares
Last Trade
Dec 06, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$12 75 shares
$0.16
$0.03
NKGen Biotech
NKGen Biotech NKGN
Chief Executive Officer
Holding Value $10.3k 170,969 shares
Last Trade
Dec 05, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$350 105 shares
$3.33
$0.06
Graf Acquisition IV
Graf Acquisition IV GFOR
Chief Executive Officer
Holding Value $1.42M 170,969 shares
Last Trade
Dec 05, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$350 105 shares
$3.33
$8.30
NKGen Biotech- Warrants (01/09/2028)
NKGen Biotech- Warrants (01/09/2028) NKGNW
Chief Executive Officer
Holding Value $5.15k 170,969 shares
Last Trade
Dec 05, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$17.6 105 shares
$0.17
$0.03
Graf Acquisition IV
Graf Acquisition IV GFOR
Chief Executive Officer
Holding Value $1.42M 170,864 shares
Last Trade
Dec 04, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$497 162 shares
$3.07
$8.30
NKGen Biotech
NKGen Biotech NKGN
Chief Executive Officer
Holding Value $10.3k 170,864 shares
Last Trade
Dec 04, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$497 162 shares
$3.07
$0.06
NKGen Biotech- Warrants (01/09/2028)
NKGen Biotech- Warrants (01/09/2028) NKGNW
Chief Executive Officer
Holding Value $5.14k 170,864 shares
Last Trade
Dec 04, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$27.1 162 shares
$0.17
$0.03
Graf Acquisition IV
Graf Acquisition IV GFOR
Chief Executive Officer
Holding Value $1.42M 170,701 shares
Last Trade
Nov 27, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$700 243 shares
$2.88
$8.30
NKGen Biotech
NKGen Biotech NKGN
Chief Executive Officer
Holding Value $10.2k 170,701 shares
Last Trade
Nov 27, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$700 243 shares
$2.88
$0.06

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up